GLP-1 RAs inhibit platelet activation through the cAMP/PKA pathway, reduce endotoxemia-induced microvascular thrombosis, and reduce the occurrence of diffuse intravascular coagulation, thereby preventing systemic inflammation, improving vascular dysfunction, reducing organ injure, and improving the outcome of patients with sepsis (Steven et al., 2017). The gene discussed is GLP1R; the disease is serum lipopolysaccharide activity.